Cooley advised Gimmal, a developer of information management and enterprise content management software and a portfolio company of Rubicon Technology Partners, on its acquisition by Morae Global, a provider of legal and compliance consulting services
Nuvation Bio Announces up to $250 Million Nondilutive Financings From Sagard Healthcare Partners
February 18, 2025
Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.
Brigit Announces up to $460 Million Sale to Upbound Group
December 12, 2024
Cooley advised Brigit, a financial health technology company, on its definitive agreement to be acquired by Upbound Group (Nasdaq: UPBD), a technology- and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, for total consideration of up to $460 million.
Longboard Pharmaceuticals Announces $2.6 Billion Sale to Lundbeck
October 14, 2024
Cooley advised Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, on its $2.6 billion sale to Lundbeck.
Expert Institute Announces Sale to Levine Leichtman Capital Partners
September 30, 2024
Cooley advised Expert Institute (EI), a provider of outsourced legal services to the attorney market, on its acquisition by Levine Leichtman Capital Partners, a Los Angeles-based private equity firm, from Spectrum Equity, a growth equity firm that provides capital and strategic support to innovative companies in the information economy, in partnership with management.